Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention

NCT01848106 is registered in ClinicalTrials.gov with Regado Biosciences, Inc. as lead sponsor.

NCT NCT01848106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01848106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention
Lead sponsor
Regado Biosciences, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2013
Completion date
August 31, 2014
Enrollment
3,232 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease